Related Experiment Video
Updated: May 23, 2025
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
Published on: March 16, 2022
Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery
Devesh U Kapoor1, Geeta Patel2, Bhupendra G Prajapati3,4,5
1Dr. Dayaram Patel Pharmacy College, Bardoli, 394601, Gujarat, India.
Opinion Statement:
Ocular cancers, though rare, present significant therapeutic challenges due to their aggressive nature, high metastatic potential and anatomical constraints that limit drug delivery. Conventional therapies, including radiation, enucleation, and chemotherapy, often result in significant side effects and suboptimal outcomes. Recent advancements in nanomedicine offer promising alternatives, utilizing NPs for targeted drug delivery, gene therapy, photodynamic therapy, and brachytherapy. Nanocarriers such as liposomes, polymeric NPs, and lipid-based NPs improve drug bioavailability, reduce systemic toxicity, and enhance treatment efficacy. Additionally, gold and silver NPs serve as effective radiosensitizers, optimizing radiation therapy. Preclinical and clinical studies indicate the potential of nanomedicine-based approaches to revolutionize ocular cancer treatment. However, challenges remain, including optimizing nanoparticle formulations and addressing regulatory hurdles. This review underscores the transformative role of nanotechnology in major and deadly ocular cancers mainly Uveal Melanoma and Retinoblasoma and emphasized cutting-edge drug delivery systems poised to improve therapeutic precision, minimize side effects, and improve patient survival and quality of life.
Insights
Nanomedicine offers new hope for treating aggressive ocular cancers like uveal melanoma and retinoblastoma. Nanoparticles improve drug delivery and reduce side effects, potentially revolutionizing treatment and improving patient outcomes.
Area of Science:
- Oncology
- Nanomedicine
- Ophthalmology
Background:
- Ocular cancers are rare but aggressive, posing significant treatment challenges due to drug delivery limitations and severe side effects from conventional therapies.
- Current treatments like radiation, enucleation, and chemotherapy have suboptimal outcomes and considerable toxicity.
- Nanomedicine presents a promising avenue for overcoming these challenges in ocular cancer treatment.
Purpose of the Study:
- To review the transformative role of nanotechnology in treating major ocular cancers, specifically uveal melanoma and retinoblastoma.
- To highlight advanced drug delivery systems utilizing nanoparticles (NPs) for enhanced therapeutic precision.
- To emphasize the potential of nanomedicine to minimize side effects and improve patient survival and quality of life.
Main Methods:
- Review of preclinical and clinical studies on nanomedicine applications in ocular cancer.
- Analysis of various nanocarriers (liposomes, polymeric NPs, lipid-based NPs) for targeted drug delivery and improved bioavailability.
- Evaluation of nanoparticles (gold, silver NPs) as radiosensitizers to enhance radiation therapy efficacy.
Main Results:
- Nanoparticles enhance drug delivery, improve bioavailability, and reduce systemic toxicity in ocular cancer models.
- Nanocarriers facilitate targeted drug delivery, gene therapy, photodynamic therapy, and brachytherapy.
- Gold and silver nanoparticles act as effective radiosensitizers, optimizing radiation therapy outcomes.
Conclusions:
- Nanomedicine, particularly through advanced nanoparticle formulations, holds transformative potential for treating ocular cancers like uveal melanoma and retinoblastoma.
- These cutting-edge drug delivery systems promise to improve therapeutic precision and minimize adverse effects.
- Further research and regulatory navigation are essential to fully realize the benefits of nanomedicine in improving patient survival and quality of life for ocular cancer patients.
Related Concept Videos
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...